Sajid A. Khan, MD earned his medical degree from the State University of New York Health Science Center at Syracuse and is Board Certified in both Complex General Surgical Oncology and General Surgery. He completed general surgery training at Oregon Health and Science University in Portland, OR and Albert Einstein College of Medicine/Montefiore in the Bronx, NY. He also completed a research fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center in New York, NY and a clinical and research fellowship in surgical oncology at The University of Chicago Medical Center in Chicago, IL.
As a surgical oncologist, Dr. Khan is dedicated to improving the lives of patients with cancer through his clinical practice and research endeavors. His clinical practice specializes in the surgical management of patients with benign and malignant tumors of the liver, pancreas, bile ducts, gallbladder, stomach, colon, and rectum. Additionally he treats individuals diagnosed with cutaneous malignancies and soft tissue sarcomas of the retroperitoneum and extremities. His commitment to the care of his patients incorporates a multidisciplinary team approach in addition to state of the art minimally invasive surgical techniques. In addition to his clinical practice, Dr. Khan is also involved in clinical translational research studying cancer metastasis. Using molecular and clinical markers, he identifies patients with a limited number of metastases (oligometastasis) who will benefit from curative local therapies, including surgical resection. He also performs clinical outcomes research in all types of gastrointestinal cancers. Dr. Khan has been recognized for excellence in both clinical care and research in oncology.
Accepts new patients? Yes
Patient Type: Adult; Geriatric
Referrals: From patients or physicians
Patient Care Organizations
Surgery, General AB of Surgery (2012)
Complex General Surgical Oncology AB of Surgery (2015)
|Pancreas||Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma|
|Colon||S0820, Adenoma and Second Primary Prevention Trial (PACES)|